Patent Application
20100119119
The invention relates generally to automated systems and methods for screening zebrafish.
Zebrafish is a well-known vertebrate model for developmental biology, molecular genetics, and toxicology studies. Zebrafish offer many advantages over other research models such as mice including the small size of zebrafish, low husbandry costs, ex utero transparent embryos, early morphology distinction, large number of embryos produced per mating, and the similarity of its genome to that of humans. Zebrafish are commonly used to study the toxicological effect of various drugs on cell apoptosis, organ development (e.g. brain, liver, tail, ear) as well as cardiac and nervous system functions, such as specific teratogenicity assays. Generally teratogenicity screens should be able to process large number of samples, provide progressive development, relate to teratogenicity mechanisms, and easy to run and interpret. T. J. Haley W. O. Brendt; Toxicology; (1987), p. 265.
Research using zebrafish as a model organism has extended to modeling human diseases and analyzing the formation and functions of cell populations in organs within the organism. This work has generated new human disease models and has begun to identify potential therapeutics, including genes that modify disease states and chemicals that rescue organs from disease.
The recent development of the zebrafish as a model for chemical genetics has established chemical screening in vivo as an adjunct to older screening technologies in cell lines or in vitro. Soluble chemicals permeate into zebrafish embryos and produce specific effects. In contrast to screening by in vitro techniques, zebrafish offers an in vivo vertebrate model for studying the bioactivity of chemicals. In addition, the availability of large numbers of zebrafish mutants makes chemical suppressor screens fast and straightforward. The targets of chemicals found to prevent or cure disease phenotypes in zebrafish will, in general, have very close cognates in humans. Therefore these screens promise to provide key entry points for the development of new therapeutic drugs.
In contrast to other vertebrate models, zebrafish complete embryogenesis in the first 72 hours post fertilization. Most of the internal organs, including the cardiovascular system, gut, liver and kidney, develop rapidly in the first 24 to 48 hour. Zebrafish embryos are also transparent, which facilitates observation and analysis. All the precursor tissues of the brain, eyes, heart and musculature can be easily visualized using light microscopy. Another important advantage of this animal model is that the morphological and molecular basis of tissue and organ development is, in general, either identical or similar to other vertebrates, including humans. Since single embryos can be maintained in fluid volumes as small as 100 μl for the first five to six days of development, they can be kept in individual microtiter wells. Reagents can then be added directly to the solution in which the embryos develop, simplifying drug dispensing and facilitating analysis. Zebrafish embryos, which are permeable to small molecules, provide easy access for drug administration and vital dye staining. Small molecules, including peptides, dyes and drugs can be simply dissolved in fish water and taken up by the zebrafish in the absence or presence of a carrier (e.g., 0.1% dimethyl sulfoxide, DMSO). Compound treatment can be performed in 96- or 384-well microwells using conventional liquid handling and quantitative ELISA formats. Use of zebrafish as an alternative animal model for drug screening can greatly accelerate the drug screening process, decrease costs, and provide more accurate results than cell-based assays. Use of zebrafish as an alternative animal model for mammals (e.g., rodents, primates, etc.) in preclinical drug screening can greatly accelerate the discovery process, decrease costs, and allow higher throughput than traditional animal studies. Use in drug and environmental toxicology can increase throughput and alleviate some of the animal rights concerns.
However, such studies rely on various measurements such as, but not limited to, liver size, tail length and curvature, size and frequency of spots, and the presence or absence of axons. At present, these measurements are typically obtained manually, or using generic imaging software and manual tracing of image features. Such methods are time consuming and inefficient given the small size of these research models and subject to human bias.
Currently, automated, high-content, medium- or high-throughput systems and methods do not exist for measuring and quantifying the effects of compounds on zebrafish and zebrafish development.
The systems and methods of one or more of the embodiments facilitate toxicology studies in zebrafish, by providing high-content, medium-throughput, automated systems and methods for screening zebrafish for evidence of toxicity. These systems and methods enable in vivo assessment of compounds and environmental chemicals and their side effects in zebrafish over time and across different doses. When used in high-content, automated systems, the systems and methods enable rapid, automated and extensive compound screening such as the screening of compound libraries.
An embodiment of the system of the invention for screening zebrafish generally comprises: a storage device for at least temporarily storing an image of a zebrafish to be screened; a zebrafish atlas; and an operating device that automatically screens the zebrafish at least in part by automatically comparing one or more anatomical features of the zebrafish, determined in part using the zebrafish atlas, to one or more standards; wherein one or more of the anatomical features of the zebrafish may comprise measurements of the zebrafish, body, notochord, tail, trunk, pericardial edema region, eye, head, abdomen, swim bladder, jaw, heart chamber, gastrointestinal tract, or liver. The anatomical features of the zebrafish comprise spots, brain color, brain texture, tail shape, somite shape, eye pigmentation, body pigmentation, straightness of the notochord, fin shape, intestine shape, intestine color, existence of axons, or cell or tissue necrosis. The atlas of the system may also be is automatically adaptable. The standards may comprise, but are not limited to, a control fish, a previous image of the zebrafish, a library-based standard, or an amalgamation of a plurality of fish.
The operating device may also identify a strain to which the zebrafish corresponds, wherein the strain may be identified at least in part by comparing the zebrafish to a library of candidate zebrafish strains accessible to the operating system, or by comparing one or more of the anatomical features to one or more of the candidate zebrafish strains in the library. The anatomical features may comprise one or more measurements of the zebrafish, wherein the operating device screens the zebrafish for toxicity at least in part by comparing one or more of the measurements to a toxicity standard. The measurements may comprise one or more of length, area, curvature, color, texture, shape, intensity and combinations thereof. The operating device may screen the zebrafish at least in part by automatically identifying one or more developmental defects in the zebrafish.
The system may also further comprise an imaging device to create one or more images of the zebrafish to be screened. The imaging device may be used, for example, to take a plurality of images of the zebrafish at various levels of resolution, wherein one of the images may be a lower resolution image of the entire zebrafish and one of the images is a higher resolution image of one or more organs within the zebrafish. The operating system may be configured to apply real-time atlas analysis to one or more low-resolution images, to initiate acquisition of one or more high-resolution images, at least in part by identifying the organ and centering the organ in a high magnification field of view. The imaging device may also take a plurality of images at various levels of resolution automatically, based at least in part, on the comparison of the image of the zebrafish to the zebrafish atlas.
The storage device may also store information on one or more agents, and wherein the operating device gathers data relating to one or more organs within the zebrafish and correlates the data with the information on one or more agents, wherein the operating device may determine one or more levels of toxicity based on the correlation of the organ data to the agent information.
An example of the method of the invention for screening zebrafish generally comprises: providing an image of a zebrafish to be screened; providing a zebrafish atlas and automatically measuring one or more anatomical features of the zebrafish at least in part using the atlas; and screening the zebrafish at least in part by automatically comparing one or more of the anatomical features of the zebrafish to one or more standards. The measurements and standards may comprise one or more of length, area, curvature, color, texture, shape, intensity and combinations thereof. The method may further comprise automatically determining a developmental stage of the zebrafish, such as, broad embryo, larval and adult stages, and more specific sub-stages.
The anatomical features of the zebrafish may comprise the zebrafish body, notochord, tail, trunk, pericardial edema region, eye, head, abdomen, swim bladder, jaw, heart chamber, gastrointestinal tract, or liver. The anatomical features of the zebrafish may also comprise spots, brain color, brain texture, tail shape, somite shape, eye pigmentation, body pigmentation, straightness of the notochord, fin shape, intestine shape, intestine color, existence of axons, or cell or tissue necrosis.
The standards may comprise, but are not limited to, a control fish, a previous image of the zebrafish, a library-based standard, or an amalgamation of a plurality of fish, wherein the amalgamation may comprises a computed statistic of one or more features of the plurality of fish that correspond to the anatomical features of the zebrafish.
The method may further comprise identifying a strain to which the zebrafish corresponds wherein the strain is identified at least in part by automatically comparing the zebrafish to a library of candidate zebrafish strains accessible to the operating system. The method may also determine a phenotype or genotype of the zebrafish.
If the zebrafish is being screened for toxicity, the toxicity may be screened at least in part by automatically identifying one or more developmental defects in the zebrafish. The method may also comprise determining one or more levels of toxicity in one or more organs of the zebrafish.
These and other features, aspects, and advantages of the present invention will become better understood when the following detailed description is read with reference to the accompanying drawings in which like characters represent like parts throughout the drawings, wherein:
The systems and methods of one or more of the embodiments enable medium-throughput, automated screening of toxicity in zebrafish, and in some more specific embodiments, the type and extent of toxicity may be determined. The systems and methods can readily make use of libraries of zebrafish phenotypes and genotypes, as well as libraries relating to agents, biomarkers and probes.
One or more of the embodiments may also be configured to generate scores based on a combination of measurements and/or other information relevant to research. For example, for a given assay, a set of morphological and textural descriptors may be extracted from each fish being screened, as well as for specific organs and subparts of organs within the fish. In one or more of the embodiments of the systems and methods, an atlas of a zebrafish is used as the standard or model to which the zebrafish, being screened, is compared. Such shape and appearance descriptors are stored, in some of the embodiments of the systems, as metadata, or are otherwise accessible to the system's operating subsystem. In one or more example embodiments, a query regarding a particular fish will result in various scores for individual toxicology endpoints. In one or more example embodiments, a query regarding a particular toxicology endpoint will produce the fish that have high scores for specific features relating to that endpoint.
One or more of the embodiments of the methods and systems are adapted for toxicology screening, by which toxicity is quantitatively assessed on a continuous scale and phenotypes are objectively identified based, as a nonlimiting example, on their morphometric or relative intensity features.
To more clearly and concisely describe and point out the subject matter of the claimed invention, the following definitions are provided for specific terms, which are used in the following description and the appended claims. Throughout the specification, exemplification of specific terms should be considered as non-limiting examples.
As used herein, the term “atlas” refers to a digitized graphical representation of an organism's anatomy ontology. The atlas may be a graphical representation of the entire organism or may be divisible into portions or regions of the organism. The atlas may be a representation of various types or versions of an organism including, but not limited to, normal, wild-type, mutant, transgenic, agent-treated, probe-treated, genetically engineered, modified, or artificially created, organisms. The representation may be from a single organism or may be synthesized, or otherwise computed or artificially created (e.g. averaged), from a group or groups of organisms. The atlas may comprise one or more of a representation of an organism on which the spatial extent and coordinates of the representation is defined; an ontology of terms; and a mapping, or interpretation, between the representation and the ontology. The ontology may comprise the structural changes that occur during development of the organism (e.g. embryonic development stages) and may further comprise one or more hierarchies, for each development stage, wherein a stage may be characterized by internal and external morphological features of the organism.
As used herein, the term “annotation” refers to words, symbols, letters, images, numbers, marks and phrases that may be added, deleted, amended, or replaced. Annotations may be entered by the system based on preset guidelines or rules or by system-adaptable guidelines or rules, or by a user of the system. The annotations may be entered manually, automatically, or electronically using a keyboard, a stylus, touchpad, or using verbal identification software. The means of entry may be wired or wireless. Annotations may be, but are not limited to, semantic, textual, explanatory, commentary, illustrative, automated, pictorial, auditory, or linguistic in nature. Annotations may be visible to the viewer on-screen, embedded, hypertext, archived or retrievable, without limitation.
As used herein, the term “agent” refers to any element, compound, compound cocktail or entity including, but not limited to, e.g. pharmaceutical, therapeutic, pharmacologic, environmental or agricultural pollutant or compound, toxin, aquatic pollutant, cosmeceutical, drug, toxin, natural product, synthetic compound, or chemical compound.
As used herein, the terms “biomarker” and “channel marker” include, but are not limited to, fluorescent imaging agents and fluorophores that are chemical compounds, which when excited by exposure to a particular wavelength of light, emit light at a different wavelength. Fluorophores may be described in terms of their emission profile, or “color.” Green fluorophores (for example Cy3, FITC, and Oregon Green) may be characterized by their emission at wavelengths generally in the range of 515-540 nanometers. Red fluorophores (for example Texas Red, Cy5, and tetramethylrhodamine) may be characterized by their emission at wavelengths generally in the range of 590-690 nanometers. An examples of an orange fluorophore is a derivative of 1,5-bis{[2-(di-methylamino) ethyl]amino}-4, 8-dihydroxyanthracene-9,10-dione (CyTRAK Orange™) that stains both nucleus and cytoplasm, and examples of far-red fluorophores are 1,5-bis{[2-(di-methylamino) ethyl]amino}-4,8-dihydroxyanthracene-9,10-dione (DRAQ5™) a fluorescent DNA dye and 1,5-bis({[2-(di-methylamino) ethyl]amino}-4,8-dihydroxyanthracene-9,10-dione)-N-Oxide (APOPTRAK™) a cellular probe. Examples of fluorophores include, but are not limited to, 4-acetamido-4′-isothiocyanatostilbene-2,2′disulfonic acid, acridine, derivatives of acridine and acridine isothiocyanate, 5-(2′-aminoethyl)aminonaphthalene-1-sulfonic acid (EDANS), 4-amino-N-[3-vinylsulfonyl)phenyl]naphthalimide-3,5 disulfonate (Lucifer Yellow VS), N-(4-anilino-1-naphthyl)maleimide, anthranilamide, Brilliant Yellow, coumarin, coumarin derivatives, 7-amino-4-methylcoumarin (AMC, Coumarin 120), 7-amino-trifluoromethylcouluarin (Coumaran 151), cyanosine; 4′,6-diaminidino-2-phenylindole (DAPI), 5′,5″-dibromopyrogallol-sulfonephthalein (Bromopyrogallol Red), 7-diethylamino-3-(4′-isothiocyanatophenyl)-4-methylcoumarin, -, 4,4′-diisothiocyanatodihydro-stilbene-2,2′-disulfonic acid, 4,4′-diisothiocyanatostilbene-2,2′-disulfonic acid, 5-[dimethylamino]naphthalene-1-sulfonyl chloride (DNS, dansyl chloride), eosin, derivatives of eosin such as eosin isothiocyanate, erythrosine, derivatives of erythrosine such as erythrosine B and erythrosin isothiocyanate; ethidium; fluorescein and derivatives such as 5-carboxyfluorescein (FAM), 5-(4,6-dichlorotriazin-2-yl) aminofluorescein (DTAF), 2′7′-dimethoxy-4′5′-dichloro-6-carboxyfluorescein (JOE), fluorescein, fluorescein isothiocyanate (FITC), QFITC (XRITC); fluorescamine derivative (fluorescent upon reaction with amines); IR144; IR1446; Malachite Green isothiocyanate; 4-methylumbelliferone; ortho cresolphthalein; nitrotyrosine; pararosaniline; Phenol Red, B-phycoerythrin; o-phthaldialdehyde derivative (fluorescent upon reaction with amines); pyrene and derivatives such as pyrene, pyrene butyrate and succinimidyl 1-pyrene butyrate; Reactive Red 4 (Cibacron™ Brilliant Red 3B-A), rhodamine and derivatives such as 6-carboxy-X-rhodamine (ROX), 6-carboxyrhodamine (R6G), lissamine rhodamine B sulfonyl chloride, rhodamine (Rhod), rhodamine B, rhodamine 123, rhodamine X isothiocyanate, sulforhodamine B, sulforhodamine 101 and sulfonyl chloride derivative of sulforhodamine 101 (Texas Red); N,N,N′,N′-tetramethyl-6-carboxyrhodamine (TAMRA); tetramethyl Rhodamine, tetramethyl rhodamine isothiocyanate (TRITC); riboflavin; rosolic acid and lathanide chelate derivatives, quantum dots, cyanines, pyrelium dyes, and squaraines.
As used herein, the term “developmental defect” refers to deficiency, imperfection, or difference in the development of a tissue, organ, or other bodily component of an organism relative to normal development. Such a defect may be identified as a change, difference, or lack of something necessary or desirable for completion or proper operation in the development of a tissue, organ, or other bodily component of an organism.
As used herein, the term “organ” refers to a group of tissues that perform a specific function or group of functions (e.g. heart, lungs, brain, eye, stomach, spleen, bones, pancreas, kidneys, liver, intestines, skin, urinary bladder and sex organs).
As used herein, the term “probe” refers to an agent having a binder and a label, such as a signal generator or an enzyme. In some embodiments, the binder and the label (signal generator or the enzyme) are embodied in a single entity. The binder and the label may be attached directly (e.g., via a fluorescent molecule incorporated into the binder) or indirectly (e.g., through a linker, which may include a cleavage site) and applied to the biological sample in a single step. In alternative embodiments, the binder and the label are embodied in discrete entities (e.g., a primary antibody capable of binding a target and an enzyme or a signal generator-labeled secondary antibody capable of binding the primary antibody). When the binder and the label (signal generator or the enzyme) are separate entities they may be applied to a biological sample in a single step or multiple steps. As used herein, the term “fluorescent probe” refers to an agent having a binder coupled to a fluorescent signal generator.
As used herein, the term “toxin” refers to any substance that has the potential to cause harm to the organism.
As used herein, the term “standard” includes, but is not limited to, any information that serves as a baseline for comparison. For example, a standard may comprise, but is not limited to, one or more real or artificially created or defined parameters or points (e.g. length, area, curvature, color, texture, shape, intensity, combinations thereof), a control fish, a previous image of the zebrafish (e.g. taken prior to application of an agent or probe), a predetermined standard (e.g. stored library of standards, expert-based standard), a baseline created in real-time with the analysis (e.g. automatically by the system or manually by a user), defined by a subpopulation (e.g. manually or automatically), a control run, a longitudinal study-based standard (e.g. based on a fixed time point of a single or population), or an amalgamation of a plurality of fish. An amalgamation may comprise a computed statistic of one or more features, for example, of the plurality of fish or a plurality of images of the one or more fish, which correspond to the anatomical features of interest of the zebrafish being screened.
The example methods and systems automate the analysis of zebrafish for various research and screening studies such as toxicology studies. Measurements of the fish, such as, but not limited to, the length of the fish, number of spots on the head and tail, curvature of the tail, and liver shrinkage are carried out automatically using various shape descriptors based on models of the fish. These measurements can then be used, for example, to compute various drug-related indicators such as dose response, half maximal effective concentration (EC50), and half maximal inhibitory concentration (IC50). Images may be acquired by various modalities as in transmitted light and fluorescence imaging, each in various spectral bands, or in combination constituting hyperspectral imaging. The shape descriptors may be stored in a database in a memory device in the system or otherwise accessible to the system via a removable memory device or through a server. These shape descriptors facilitate the search and comparison of fish phenotypes to the organism of interest being screened. Furthermore, such databases can be integrated with other zebrafish databases (e.g., gene databases on ZFIN). The extraction of shape and appearance features at the organ level mimics the current approach of toxicologists. However, the database may also serve as a discovery tool in which several features can be combined to qualify a phenotype. It is to be understood that correlation and clustering patterns of several phenotypes may constitute emergent signs of toxicity not easily detected by human visual inspection, on small organisms or the higher mammals.
One aspect of the methods and systems is to enable detection and identification of the development stage of a zebrafish. Depending on the organism of interest, the developmental stage of a given zebrafish is important when detecting and identifying the anatomy of the zebrafish. At least one of the example embodiments of the methods and systems detects the developmental stage of the zebrafish automatically. Another aspect of the methods and systems is to enable detection and identification of the viability of the zebrafish for the initial screening before the start of compound treatment studies (dead vs. alive).
For example, zebrafish are transparent during their embryonic stage. For various applications the developmental stages of the zebrafish are important, nonlimiting examples of which are listed below:
6 hours: at six hours, as a measure of quality control, it is possible to detect whether fertilization is successful;
48 hours: at forty-eight hours it is possible to determine whether the heart function and morphology deviate from the norm;
96 hours: at ninety-six hours it is possible to determine whether gastrointestinal toxicity has occurred, also swim bladder can be analyzed;
120 hours: at one hundred twenty hours it is possible to test for liver toxicity.
Anatomical features that are relevant to toxicity in zebrafish include, but are not limited to, the overall zebrafish body, notochord, tail, trunk, pericardial edema, eye, head, abdomen, swim bladder, jaw, heart chamber, gastro-intestinal tract, and liver. The anatomical features of the zebrafish may also comprise general spots, brain color, brain texture, tail shape, somite shape, eye pigmentation, body pigmentation, cardiac change (e.g. over time), straightness of the notochord, fin shape, intestine shape, intestine color, existence of axons, or cell or tissue necrosis.
For example,
Evaluation protocols are formulated for a given developmental stage of the organism. For example, below is an example protocol for evaluating a 5-day old zebrafish (120 hours):
Heart morphology: Assessment of overall heart morphology and function. The physical structure of the heart can be investigated. Flow asynchronies may also be monitored. Various morphological features can be measured such as pericardial edema length, to determine and detect abnormalities, and cardiac changes over time.
Trunk/swim bladder: Screening for edema in the region of the head.
Hemorrhage: Detect areas of accumulated blood. These areas will appear as dark red spots on the fish.
Brain morphology: Using both axial and sagittal views of the fish, changes in brain morphology can be used to determine and detect abnormalities.
Brain Tissue Toxicity effects on the brain can be determined using the color and texture of the brain. For example, brain tissue becomes opaque and the overall intensity of the image will be considerably darker.
Jaw morphology: Subtle changes in the head morphology may indicate that the jaw development has been affected.
Tail morphology: Changes in the shape of the tail, such as curvature and kinks (
Eye pigmentation: Regions of the eye that are no longer black indicate that pigment cells no longer exist and the eye will become transparent.
Body pigmentation: Changes in the overall number of black spots on the surface of the fish may indicate developmental defects.
Notochord morphology: The notochord of a normal fish is delineated by two virtually parallel lines. When these lines become wavy or other wise are not straight, this may indicate developmental defects.
Fin morphology: Using an axial or dorsal view, when the fins on the side of the fish are malformed or have not developed, this may indicate a developmental defect.
Liver tissue: Changes in the color and texture of the liver may be indicative of defects. For example, the color of the liver may turn brown and the tissue may appear not to have any surface texture.
Intestine morphology: Malformation of the gastrointestinal tract may be indicative of defects.
Intestine tissue: The tissue of a normal GI tract is slightly yellow and it is possible to visualize folds in the intestine. Changes in color and the folds in the intestine may be indicative of defects.
Another feature of some of the embodiments of the methods and systems is automated image analysis. Automated image analysis enables process standardization that is very important for screening the effects of drugs and toxins on zebrafish and their organ development. For example, automated image analysis of zebrafish enables repetitive tasks, detect rare events, quantify the extent of different stains, classify and count numerous features, and answer questions that are beyond the capabilities of manual microscopy. In the context of modeling, it is essential to have quantified data of the biological and image-based experiments. High-throughput image analysis is the most practical way to accomplish such a task.
Another feature of one or more of the embodiments is to detect and identify the anatomical structures of the organism in part by comparing a zebrafish to be screened with a digital zebrafish atlas. At least one embodiment of the methods and systems may be configured to detect and identify the various developmental stages of the organism. Although the atlas may be constructed in various ways, at least one embodiment of the atlas is constructed using a 2-dimensional deformable mesh. A given set of measurements may be defined using the vertices of the mesh.
The atlas for a given organism should capture all the relevant regions of the organism. A non-limiting example of such an atlas is shown in
Atlases may also be created for a variety of uses such as phenotyping studies. For example, atlases may be created for a sub-population such as a mutant strain or for subpopulations used in knock-out studies.
In one or more of the embodiments of the methods and systems, an automatic fitting algorithm is used to register or otherwise match or compare the atlas to the example of the individual fish. Once registered, the system may be configured to carry out a variety of measurements and analyze the sample fish being tested. The type of measurements and analysis can be automatically generated by the system based on, for example, the type of organism, assay or test. The user may also make selections or enter customized instructions into the system as needed.
As shown in
As another example, if a given assay requires the measurement of the uptake of a fluorescent marker in a region of the zebrafish notochord, a user could mark the region as a region of interest in the atlas. The system could then measure and/or analyze the region of interest and generate a report or analysis of one or more features or characteristics of the region or sub-region.
A feature of one or more of the embodiments, when using an atlas, is the ability of the system to automatically carry out anatomically relevant measurements as defined by the structure of the atlas. Once the atlas is registered to a particular fish sample, any or all of the measurements can be computed automatically. An example of a possible set of area and length measurements is shown in
AB body length
BC notochord length
BD tail length
AD trunk length
EF pericardial edema length
GH eye size
IJ head width
KL abdominal width
Swim bladder
Heart chamber
Gastro-intestinal tract
A general flow diagram is shown in
Key features may be detected using an algorithm comprising, for example to detect a zebrafish eye, a multi-resolution Hough circle fitting algorithm with a binary search for optimal radius. Zebrafish whole-body segmentation may be achieved, but is not limited to, using an algorithm comprising quadtree decomposition of the image based on region variance and merging similar blocks.
After the preprocessing step and before the measurements are extracted, the atlas, an example of which is shown in
Automated atlas registration is used to fit the shape and key body regions of an organism, such as the zebrafish, to its digital atlas so that certain anatomical measurements can be automatically estimated or determined. The preprocessing step identifies one or more regions of interest in the organism. A global registration is applied to estimate the overall orientation and position of the organism in the image. Given the resulting region of interest, comprising one sample organism, the outline of the organism is identified using image segmentation. In one of the embodiments, a quad-tree method for image segmentation is applied to identify the outline of the sample.
An active shape model (ASM) algorithm may be employed to register the atlas to a sample. ASM comprises a shape model and an appearance model. Shape is represented using a set of pre-specified landmarks. ASM captures shape variations by training a principal component analysis (PCA) model from observed data. At each landmark, a local texture model is obtained by training a Gaussian model using the observed profile texture along the normal direction of the shape contour. Since organism shape can vary substantially from the norm, the outline of the organism is used to initialize the ASM algorithm at a solution very close to its global optima.
As shown in
Measurements of a sample organism may be compared to a predetermined range of measurements to determine, for example, whether a given measurement falls outside of the normal range of measurements. High-throughput screening measurements may also, for example, be extracted for all organisms screened in a given run. Parameters such as, but not limited to, mean and variance, may be used to differentiate between normal, wild type, abnormal, and treated and untreated organisms, as well as toxicity and levels of toxicity. Measurements are not limited to geometrical measurements and may include, but are not limited to, variations in length, area, curvature, color, texture, shape, intensity and combinations thereof.
A dataset of measurements were automatically generated from eleven normal zebrafish, eight wild type zebrafish and one treated zebrafish after an atlas was fitted to the set of fish.
The methods and systems may be configured to identify the developmental stage of an organism and to identify specific organs and sub-regions within the organs. Once identified, information about the organs and sub-regions may be further used to correlate the information according to an assay and/or an image of one or more fluorescent-based channel. An atlas of the organism is used in one or more of the embodiments to automatically locate the different organs in a zebrafish, for example, and then correlate the information to a predetermined set of rules or guidelines.
One or more of the embodiments of the methods and systems may comprise the steps and hardware for automatically acquiring one or more images of the sample organism. These automated imaging acquisition steps and the hardware needed for imaging the organism may be incorporated into automated, high-throughput screening systems such as an IN Cell Analyzer system available from GE Healthcare.
In a first step, a low-resolution image is taken of the sample organism to locate the position of the organism and to detect the specific location of one or more organs of interest within the organism. This information is then applied to automatically change the objective of the system and position a movable stage to take a high-resolution image of the organ of interest. An atlas is also used in one or more of the embodiments to correct or otherwise automatically enhance an image, for example, by image stitching.
The system may comprise an imaging device that is configured to automatically employ the atlas at lower resolution to determine the areas of interest and focus and image at higher resolution on the regions of the organism's body. In this way the imaging throughput may be significantly increased. As an example of application, if the organism such as the zebrafish is in the wells of a 96-well plate, one 5-day post fertilization fish per well, and one is interested to imaging the heart region (size about 200 micrometer (um)), a suitable resolution may be to image with a 10× objective magnification. Under this magnification, the area of the typical field of view of an automated high content imaging system, e.g. the IN Cell Analyzer from GE Healthcare, is about 0.6 mm2. The circular well of a 96-well plate has a diameter of about 6.5 mm, or area of 33 mm2. This implies that with the 10× objective at least 50 images must be acquired in each well until the heart area is imaged.
The operating device can be used to increase the speed of the system using, for example, the following steps: (1) acquisition of a single image of the whole well under 1× magnification; (2) online use of atlas analysis to locate the near exact value of the location of the heart area; (3) automated command of the motorized XY-stage movement to laterally move and center the heart area above the optical axis; (4) automated command of the motorized objective changer to change to a 10× objective; (5) automated command of the motorized Z-stage to axially move the objective to an appropriate level above the well bottom (e.g., 300 um, for better focusing); and/or (6) acquisition of transmitted and/or fluorescent images of the heart area. In some embodiments, all of the operations can be carried out simultaneously or nearly simultaneously, depending in part on whether multiple images are acquired. This example embodiment provides advantages such as, but not limited to, (a) high resolution imaging throughput can be increased significantly (at least 25 times in this example); (b) post processing of a large number of high resolution images is not necessary (e.g., analysis, stitching, flat field correction); and (c) system memory does not need to be hampered by the acquisition of a large number of useless images where most of the fields are empty.
The automated system 50 (
The storage device 52 and the operating device 54 may be incorporated as components of an analytical device such as an automated high-speed system that images and analyzes in one system. Examples of such systems include, but are not limited to, the General Electric IN Cell Analyzer systems (General Electric Healthcare Bio-Sciences Group, Piscataway, N.J.). As noted, system 50 may further comprise a display device 56 for displaying one or more of the images of the sample organisms, the atlas, the atlas fitted on an image of the sample organism, measurement results and/or any other type of image, report or data useful for viewing by the user of the system; an interactive viewer 58; a virtual microscope 60; and/or a device for transmitting 62 one or more of the images or any related data or analytical information over a communications network 64 to one or more remote locations 66.
Display device 56 may comprise any suitable device capable of displaying a digital image such as, but not limited to, devices that incorporate an LCD or CRT. Transmitting device 62 may comprise any suitable means for transmitting digital information over a communications network including but not limited to hardwired or wireless digital communications systems. As in the IN Cell Analyzer, the system may further comprise an automated device 68 for processing assays or otherwise applying stains, markers, probes or other similar research tools; and a digital imaging device 70 such as, but not limited to, a fluorescent imaging microscope comprising an excitation source 72 and capable of capturing digital images of the sample organisms of interest. Such imaging devices may have a movable stage and may be capable of auto focusing and then maintaining and tracking the focus feature as needed.
The methods and systems may be used for a wide variety of application including, but not limited to,
Neurotoxicity
Cardiotoxicity
Liver toxicity
Kidney toxicity
Gastrointestinal toxicity
Pancreatic toxicity
High content screening of chemical libraries
Cardiac function assessment
Genotype studies
Flow Cytometry
Cell Cycle
Angiogenesis
Apoptosis
While only certain features of the invention have been illustrated and described herein, many modifications and changes will occur to those skilled in the art. It is, therefore, to be understood that the appended claims are intended to cover all such modifications and changes as fall within the true spirit of the invention.
This application is a continuation-in-part of U.S. patent application Ser. No. 12/267,019 entitled “SYSTEMS AND METHODS FOR AUTOMATED EXTRACTION OF HIGH-CONTENT INFORMATION FROM WHOLE ORGANISMS”, filed Nov. 7, 2008, which is hereby incorporated by reference.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12267019 | Nov 2008 | US |
| Child | 12403587 | US |
